The Sildenafil Dose Lesson From Children With Lung Hypertension

Sildenafil is not only an ED molecule

Sildenafil is best known to many adults as an erectile dysfunction drug.

In another medical setting, the same molecule has been studied and used for pulmonary arterial hypertension, or PAH. In PAH, high pressure in the lung arteries makes the right side of the heart work harder. Sildenafil can relax pulmonary blood vessels by inhibiting PDE5 and increasing cGMP signaling.

That mechanism sounds simple.

The pediatric evidence was not simple.

The STARTS studies created a dose puzzle

The STARTS-1 trial tested oral sildenafil in treatment-naive children aged 1 to 17 years with PAH. Children were randomized to low-, medium-, or high-dose sildenafil or placebo three times daily for 16 weeks. The primary endpoint was percent change in peak oxygen consumption for the combined sildenafil dose groups versus placebo. The combined result narrowly missed conventional statistical significance, but medium- and high-dose groups showed improvements in some secondary measures, including hemodynamics and functional class. (PubMed)

That early signal made sildenafil look biologically useful.

Then the extension study, STARTS-2, made the story harder. Long-term follow-up reported 37 deaths. Estimated 3-year survival from sildenafil start was 94% in the low-dose group, 93% in the medium-dose group, and 88% in the high-dose group. The hazard ratio for mortality was 3.95 for high dose versus low dose, though the investigators noted uncertainty about the survival-dose relationship. (PubMed)

That is the clinical issue behind Fildena sildenafil pediatric PAH dose mortality.

A drug can show hemodynamic benefit and still raise difficult long-term safety questions.

Why the result was hard to interpret

The STARTS-2 mortality signal was not a clean “drug caused deaths” finding.

Most deaths occurred in children with more severe underlying disease. In STARTS-2, most patients who died had idiopathic or heritable PAH and worse baseline hemodynamics. The published abstract states that most deaths were related to PAH progression, while also reporting higher mortality among children originally assigned to higher sildenafil doses. (PubMed)

A review of pediatric sildenafil safety described several reasons interpretation was difficult: heterogeneous diagnoses, different PAH causes, different ages, baseline imbalance, geographic variation, and the fact that investigators did not judge the deaths as directly attributable to study treatment. The same review still concluded that higher doses in the STARTS trials appeared associated with worse outcomes than lower-dose groups. (pmc.ncbi.nlm.nih.gov)

That tension is the point.

Sildenafil was not dismissed as useless.
High-dose confidence was weakened.
Pediatric dosing became a much more cautious question.

The current label reflects both benefit and caution

The current Revatio prescribing information indicates sildenafil for pediatric patients aged 1 to 17 years with WHO Group I PAH to improve exercise ability or, in children too young for standardized exercise testing, pulmonary hemodynamics thought to underlie exercise improvement. It gives pediatric dosing by weight: 10 mg three times daily for patients ≤20 kg, 20 mg three times daily for 20–45 kg, and 20 mg three times daily for patients >45 kg, with possible titration up to 40 mg three times daily in patients >45 kg if required. (FDA Access Data)

But the same label preserves the STARTS safety observation. It reports deaths of 5/55, 10/74, and 22/100 in the low-, medium-, and high-dose groups, respectively. It states that the causes of death were related to PAH progression and that a causal association for the observed dose-related mortality effect is unlikely, while still documenting the imbalance. (FDA Access Data)

That is why sildenafil dosing in pediatric PAH is not a casual extrapolation from adult ED dosing.

Why this matters for Fildena users

Fildena-style sildenafil products are usually discussed in adult sexual-performance terms: onset, dose strength, erection firmness, and price.

The pediatric PAH story shows the larger truth: sildenafil is a systemic vascular drug. Its effect depends on the disease, the patient, the dose, the endpoint, and the risk context.

An adult taking sildenafil for ED is not the same patient as a child with PAH. But the same molecule connects both settings. That should make users more careful, not more casual.

A higher dose is not automatically a better dose.
A stronger effect is not automatically a safer effect.
A vascular mechanism does not behave identically in every body.

The practical takeaway

Fildena should not be viewed only as a sexual-performance product.

Sildenafil’s pediatric PAH history shows how one molecule can move from ED to serious cardiopulmonary disease and generate both therapeutic value and difficult safety interpretation. The STARTS studies are a reminder that dose-response data can become complicated when the disease is rare, severe, and heterogeneous.

For ED users, the lesson is simpler:

Do not treat sildenafil strength as a competition.

The right dose is the medically appropriate dose, not the largest dose available.

Disclaimer

This article is for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Sildenafil or any erectile dysfunction or pulmonary-hypertension medication should be used only under the guidance of a qualified healthcare professional.

References

1. Revatio prescribing information, revised December 2024: pediatric PAH indication, pediatric dosing, and STARTS-1/STARTS-2 mortality observation. (FDA Access Data)

2. Barst RJ, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. (PubMed)

3. Barst RJ, et al. STARTS-1: randomized, double-blind, placebo-controlled dose-ranging study of oral sildenafil in treatment-naive children with PAH. (PubMed)

4. Dodgen AL, et al. Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. (pmc.ncbi.nlm.nih.gov)